Skip to main content

JADPRO Live 2022 Main banner

Conference Brochure

Tweets by JADPRO Live 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

CE credit available

Pharmacology credit available

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

P
JL1023E
Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC)
Industry Encore Posters

Favorite
JL1024E
Patient Identification for Chimeric Antigen Receptor T-Cell Therapy: Initial Insights From the CARTITUDE Program in Multiple Myeloma
Industry Encore Posters

Favorite
JL1025E
Phase 3 multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder
Industry Encore Posters

Favorite
JL1026C
Pivoting During a Pandemic: Creation of an Oncology Procedure Team
Clinical Posters

Favorite
JL1027E
Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.
Industry Encore Posters

Favorite
JL1028E
PRIMARY RESULTS OF SUBCUTANEOUS EPCORITAMAB DOSE EXPANSION IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A PHASE 2 STUDY
Industry Encore Posters

Favorite
JL1027C
Promoting Self-Care to Reduce Compassion Fatigue in Oncology Nurses and Advanced Practice Providers: An Evidence-Based Practice Implementation Project
Clinical Posters

Favorite